Thursday, October 4, 2012
Publication and contact
Xenopus model for oligodendrocyte myelination
A Xenopus model for
myelination could help identify multiple sclerosis (MS) therapeutics.
Transgenic Xenopus laevis were engineered to express a construct
consisting of a fluorescent reporter linked to the Escherichia coli
1 nitroreductase (ntr).
The construct was then placed under the control of a regulatory sequence
specific to mature oligodendrocytes. In the model, metronidazole,
a generic prodrug that is converted into a cytotoxin by ntr, induced
oligodendrocyte apoptosis and demyelination, resulting in a lower fluorescent
signal than vehicle. Also in the model, the myelinating compound retinoic
acid induced oligodendrocyte proliferation and remyelination,
resulting in a greater fluorescent signal than vehicle. Next steps could
include using the model to test new MS therapeutics.
Published online Oct. 4, 2012
Patent and licensing status
Kaya, F. et al. J.
Neurosci.; published online Sept. 12, 2012;
Contact: Andre Mazabraud, University of South Paris XI, Orsay,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]